| Item |
Information |
|
Drug Groups
|
approved; nutraceutical |
|
Description
|
The N-acetyl derivative of glucosamine. [PubChem] |
| Indication |
For the treatment and prevention of osteoarthritis, by itself or in combination with chondroitin sulfate. |
| Toxicity |
Mouse, intravenous LD50 is 4170 mg/kg. Side effects that have been reported are mainly mild gastrointestinal complaints such as heartburn, epigastric distress and diarrhea. No allergic reactions have been reported including sulfa-allergic reactions to glucosamine sulfate. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
A significant fraction of ingested glucosamine is catabolized by first-pass metabolism in the liver. |
| Absorption |
Approximately 90% of orally administered glucosamine (salt form) gets absorbed from the small intestine. |
| External Links |
|